Novo Nordisk Ends Partnership with HIMS & HERS Stock Plunges - To The Moon

NewsNews
PostsPosts
SelectionSelection

- BarcodeBarcode
  ·2025-06-24
  $Hims & Hers Health Inc.(HIMS)$ 🚨⚖️💊HIMS vs Big Pharma: Crackdown or Correction?💊⚖️🚨 $HIMS just got smacked with a seismic downgrade. Needham has pulled it off their Conviction List and downgraded the stock to Hold, following the abrupt termination of its high-profile GLP-1 distribution deal with Novo Nordisk. The stock cratered over 30% intraday to $44.08, breaking through key Fibonacci resistance and testing the 1.272 extension. But is this the end of the bull thesis or a rare asymmetric setup in disguise? This post unpacks everything, the analyst downgrade, insider sourcing claims, technical positioning, and forward setups. 📉 Catalyst: Novo Pulls the Plug Needham’s note cited “deceptive promotion” and “illegitimate Wegovy knockoffs” as reas
  3.80K 15
  43
  Share
  Report
- BarcodeBarcode
  ·2025-06-24
  $Hims & Hers Health Inc.(HIMS)$ 🚨⚖️💊HIMS vs Big Pharma: Crackdown or Correction?💊⚖️🚨 $HIMS just got smacked with a seismic downgrade. Needham has pulled it off their Conviction List and downgraded the stock to Hold, following the abrupt termination of its high-profile GLP-1 distribution deal with Novo Nordisk. The stock cratered over 30% intraday to $44.08, breaking through key Fibonacci resistance and testing the 1.272 extension. But is this the end of the bull thesis or a rare asymmetric setup in disguise? This post unpacks everything, the analyst downgrade, insider sourcing claims, technical positioning, and forward setups. 📉 Catalyst: Novo Pulls the Plug Needham’s note cited “deceptive promotion” and “illegitimate Wegovy knockoffs” as reas
  3.80K 15
  43
  Share
  Report

{"themeInfo":{"themeId":"0e4f87550d613fe05f12a314ce8a1e93","name":"Novo Nordisk Ends Partnership with HIMS & HERS Stock Plunges","description":"Novo Nordisk announced the termination of its partnership with HIMS & HERS due to concerns about formulated drug sales and misleading marketing, causing HIMS & HERS shares to plunge more than 18% premarket and widespread market attention. The cooperation involves the sale of weight loss drugs, which has dealt a major blow to the development of HIMS & HERS business.","image":"https://community-static.tradeup.com/news/1201dcc0482be040348fb8d4f228bb68","type":2,"style":4,"follow":false,"createTime":1750680944616,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":0e4f87550d613fe05f12a314ce8a1e93}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["HIMS","NVO"],"tweetCounts":1,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"Novo Nordisk Ends Partnership with HIMS & HERS Stock Plunges","tweetAmount":1,"imageIsDefault":false,"aiDerivativeIssues":[]},"tab":"all","isFinancial":true,"allList":[{"id":449201974440216,"gmtCreate":1750694705811,"gmtModify":1750782602300,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4171900329979952","idStr":"4171900329979952"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> 🚨⚖️💊HIMS vs Big Pharma: Crackdown or Correction?💊⚖️🚨 $HIMS just got smacked with a seismic downgrade. Needham has pulled it off their Conviction List and downgraded the stock to Hold, following the abrupt termination of its high-profile GLP-1 distribution deal with Novo Nordisk. The stock cratered over 30% intraday to $44.08, breaking through key Fibonacci resistance and testing the 1.272 extension. But is this the end of the bull thesis or a rare asymmetric setup in disguise? This post unpacks everything, the analyst downgrade, insider sourcing claims, technical positioning, and forward setups. 📉 Catalyst: Novo Pulls the Plug Needham’s note cited “deceptive promotion” and “illegitimate Wegovy knockoffs” as reas","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> 🚨⚖️💊HIMS vs Big Pharma: Crackdown or Correction?💊⚖️🚨 $HIMS just got smacked with a seismic downgrade. Needham has pulled it off their Conviction List and downgraded the stock to Hold, following the abrupt termination of its high-profile GLP-1 distribution deal with Novo Nordisk. The stock cratered over 30% intraday to $44.08, breaking through key Fibonacci resistance and testing the 1.272 extension. But is this the end of the bull thesis or a rare asymmetric setup in disguise? This post unpacks everything, the analyst downgrade, insider sourcing claims, technical positioning, and forward setups. 📉 Catalyst: Novo Pulls the Plug Needham’s note cited “deceptive promotion” and “illegitimate Wegovy knockoffs” as reas","text":"$Hims & Hers Health Inc.(HIMS)$ 🚨⚖️💊HIMS vs Big Pharma: Crackdown or Correction?💊⚖️🚨 $HIMS just got smacked with a seismic downgrade. Needham has pulled it off their Conviction List and downgraded the stock to Hold, following the abrupt termination of its high-profile GLP-1 distribution deal with Novo Nordisk. The stock cratered over 30% intraday to $44.08, breaking through key Fibonacci resistance and testing the 1.272 extension. But is this the end of the bull thesis or a rare asymmetric setup in disguise? This post unpacks everything, the analyst downgrade, insider sourcing claims, technical positioning, and forward setups. 📉 Catalyst: Novo Pulls the Plug Needham’s note cited “deceptive promotion” and “illegitimate Wegovy knockoffs” as reas","images":[{"img":"https://community-static.tradeup.com/news/79328abad4c9ca0a6f5bd0b41989f707","width":"945","height":"802"},{"img":"https://community-static.tradeup.com/news/e39db06e6808a939d232d10742e72ec8","width":"947","height":"544"},{"img":"https://community-static.tradeup.com/news/851acebd6f76602936c2f265188e628d","width":"1115","height":"644"}],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":43,"commentSize":15,"repostSize":105,"link":"https://ttm.financial/post/449201974440216","isVote":1,"tweetType":1,"viewCount":3798,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4172287591330932","authorId":"4172287591330932","name":"Hen Solo","avatar":"https://community-static.tradeup.com/news/e8f9d57b757c07c87986ef8a0be25085","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4172287591330932","idStr":"4172287591330932"},"content":"📚🔍💥That $44.52 level is exactly where I’d expect the chart to tell the truth. Appreciate how you laid out the scenarios, especially the macro view around platform wars. This isn’t just a $HIMS problem, it’s a telehealth paradigm shift unfolding in real time.","text":"📚🔍💥That $44.52 level is exactly where I’d expect the chart to tell the truth. Appreciate how you laid out the scenarios, especially the macro view around platform wars. This isn’t just a $HIMS problem, it’s a telehealth paradigm shift unfolding in real time.","html":"📚🔍💥That $44.52 level is exactly where I’d expect the chart to tell the truth. Appreciate how you laid out the scenarios, especially the macro view around platform wars. This isn’t just a $HIMS problem, it’s a telehealth paradigm shift unfolding in real time."},{"author":{"id":"4186117467483482","authorId":"4186117467483482","name":"Cool Cat Winston","avatar":"https://community-static.tradeup.com/news/00bf531d62a6793687bac561025edfdb","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4186117467483482","idStr":"4186117467483482"},"content":"🌟🧠📉I’ve been watching $HIMS closely and this situation with Novo honestly feels like more of a chess move than a real compliance breach. If their sourcing is in fact identical, I’d argue this drop is emotional pricing, not fundamental. Buy the dip time 😻","text":"🌟🧠📉I’ve been watching $HIMS closely and this situation with Novo honestly feels like more of a chess move than a real compliance breach. If their sourcing is in fact identical, I’d argue this drop is emotional pricing, not fundamental. Buy the dip time 😻","html":"🌟🧠📉I’ve been watching $HIMS closely and this situation with Novo honestly feels like more of a chess move than a real compliance breach. If their sourcing is in fact identical, I’d argue this drop is emotional pricing, not fundamental. Buy the dip time 😻"}],"imageCount":3,"langContent":"EN","totalScore":0}],"essenList":[{"id":449201974440216,"gmtCreate":1750694705811,"gmtModify":1750782602300,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4171900329979952","idStr":"4171900329979952"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> 🚨⚖️💊HIMS vs Big Pharma: Crackdown or Correction?💊⚖️🚨 $HIMS just got smacked with a seismic downgrade. Needham has pulled it off their Conviction List and downgraded the stock to Hold, following the abrupt termination of its high-profile GLP-1 distribution deal with Novo Nordisk. The stock cratered over 30% intraday to $44.08, breaking through key Fibonacci resistance and testing the 1.272 extension. But is this the end of the bull thesis or a rare asymmetric setup in disguise? This post unpacks everything, the analyst downgrade, insider sourcing claims, technical positioning, and forward setups. 📉 Catalyst: Novo Pulls the Plug Needham’s note cited “deceptive promotion” and “illegitimate Wegovy knockoffs” as reas","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> 🚨⚖️💊HIMS vs Big Pharma: Crackdown or Correction?💊⚖️🚨 $HIMS just got smacked with a seismic downgrade. Needham has pulled it off their Conviction List and downgraded the stock to Hold, following the abrupt termination of its high-profile GLP-1 distribution deal with Novo Nordisk. The stock cratered over 30% intraday to $44.08, breaking through key Fibonacci resistance and testing the 1.272 extension. But is this the end of the bull thesis or a rare asymmetric setup in disguise? This post unpacks everything, the analyst downgrade, insider sourcing claims, technical positioning, and forward setups. 📉 Catalyst: Novo Pulls the Plug Needham’s note cited “deceptive promotion” and “illegitimate Wegovy knockoffs” as reas","text":"$Hims & Hers Health Inc.(HIMS)$ 🚨⚖️💊HIMS vs Big Pharma: Crackdown or Correction?💊⚖️🚨 $HIMS just got smacked with a seismic downgrade. Needham has pulled it off their Conviction List and downgraded the stock to Hold, following the abrupt termination of its high-profile GLP-1 distribution deal with Novo Nordisk. The stock cratered over 30% intraday to $44.08, breaking through key Fibonacci resistance and testing the 1.272 extension. But is this the end of the bull thesis or a rare asymmetric setup in disguise? This post unpacks everything, the analyst downgrade, insider sourcing claims, technical positioning, and forward setups. 📉 Catalyst: Novo Pulls the Plug Needham’s note cited “deceptive promotion” and “illegitimate Wegovy knockoffs” as reas","images":[{"img":"https://community-static.tradeup.com/news/79328abad4c9ca0a6f5bd0b41989f707","width":"945","height":"802"},{"img":"https://community-static.tradeup.com/news/e39db06e6808a939d232d10742e72ec8","width":"947","height":"544"},{"img":"https://community-static.tradeup.com/news/851acebd6f76602936c2f265188e628d","width":"1115","height":"644"}],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":43,"commentSize":15,"repostSize":105,"link":"https://ttm.financial/post/449201974440216","isVote":1,"tweetType":1,"viewCount":3798,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4172287591330932","authorId":"4172287591330932","name":"Hen Solo","avatar":"https://community-static.tradeup.com/news/e8f9d57b757c07c87986ef8a0be25085","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4172287591330932","idStr":"4172287591330932"},"content":"📚🔍💥That $44.52 level is exactly where I’d expect the chart to tell the truth. Appreciate how you laid out the scenarios, especially the macro view around platform wars. This isn’t just a $HIMS problem, it’s a telehealth paradigm shift unfolding in real time.","text":"📚🔍💥That $44.52 level is exactly where I’d expect the chart to tell the truth. Appreciate how you laid out the scenarios, especially the macro view around platform wars. This isn’t just a $HIMS problem, it’s a telehealth paradigm shift unfolding in real time.","html":"📚🔍💥That $44.52 level is exactly where I’d expect the chart to tell the truth. Appreciate how you laid out the scenarios, especially the macro view around platform wars. This isn’t just a $HIMS problem, it’s a telehealth paradigm shift unfolding in real time."},{"author":{"id":"4186117467483482","authorId":"4186117467483482","name":"Cool Cat Winston","avatar":"https://community-static.tradeup.com/news/00bf531d62a6793687bac561025edfdb","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4186117467483482","idStr":"4186117467483482"},"content":"🌟🧠📉I’ve been watching $HIMS closely and this situation with Novo honestly feels like more of a chess move than a real compliance breach. If their sourcing is in fact identical, I’d argue this drop is emotional pricing, not fundamental. Buy the dip time 😻","text":"🌟🧠📉I’ve been watching $HIMS closely and this situation with Novo honestly feels like more of a chess move than a real compliance breach. If their sourcing is in fact identical, I’d argue this drop is emotional pricing, not fundamental. Buy the dip time 😻","html":"🌟🧠📉I’ve been watching $HIMS closely and this situation with Novo honestly feels like more of a chess move than a real compliance breach. If their sourcing is in fact identical, I’d argue this drop is emotional pricing, not fundamental. Buy the dip time 😻"}],"imageCount":3,"langContent":"EN","totalScore":0}],"allBottom":false,"essenBottom":false,"topicSource":"Post"}